Citations 2
Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
Tagawa, S, Sartor, O, Piulats, J M, Saad, F, Fizazi, K, Reid, A H, Beltran, H, Kramer, G, Eiber, M, Gupta, S, Gauna, D E Castellano, Hauke, R, Kim, H, Pang, S-T., Bouillaud, Emmanuel, Zhang, A., Sakharova, O, Morris, M J, Piulats, Josep M. , Saad, Fred , Fizazi, Karim , Reid, A H, Mahammedi, Hakim , Gupta, Shilpa , Gauna, D.E. Castellano, Hauke, Ralph J. , Kwak, Cheol Hun , Zhang, Alison Yan , Sakharova, Olga V., Morris, Michael J.
Nuklearmedizin - NuclearMedicine | April 2, 2026 | Volume: 65 | Issue: 02 | Pages: 107-107
Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore
Fizazi, Karim , Shore, N., Chi, K.N., Crosby, M. J., Roubaud, Guilhem, Fleming, Mark T. , Nordquist, L., Gauna, D.E. Castellano, Carnahan, Natalie, Ghebremariam, Samson, Hertelendi, Marianna , Eiber, Matthias , Morris, Michael J. , Bono, Johann S. de , Hermann, Ken , Nagarajah, James , Lewis, Brian E. , Sartor, Oliver
Nuklearmedizin - NuclearMedicine | March 12, 2025 | Volume: 64 | Issue: 01 | Pages: 45-46